ATE104546T1 - Lockvirus impfstoff. - Google Patents

Lockvirus impfstoff.

Info

Publication number
ATE104546T1
ATE104546T1 AT9191305706T AT91305706T ATE104546T1 AT E104546 T1 ATE104546 T1 AT E104546T1 AT 9191305706 T AT9191305706 T AT 9191305706T AT 91305706 T AT91305706 T AT 91305706T AT E104546 T1 ATE104546 T1 AT E104546T1
Authority
AT
Austria
Prior art keywords
attached
viral
microparticles
peptides
useful
Prior art date
Application number
AT9191305706T
Other languages
English (en)
Inventor
Nir Kossovsky
Rointan F Bunshah
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/542,255 external-priority patent/US5219577A/en
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE104546T1 publication Critical patent/ATE104546T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT9191305706T 1990-06-22 1991-06-24 Lockvirus impfstoff. ATE104546T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/542,255 US5219577A (en) 1990-06-22 1990-06-22 Biologically active composition having a nanocrystalline core
US07/690,601 US5178882A (en) 1990-06-22 1991-04-24 Viral decoy vaccine

Publications (1)

Publication Number Publication Date
ATE104546T1 true ATE104546T1 (de) 1994-05-15

Family

ID=27066972

Family Applications (1)

Application Number Title Priority Date Filing Date
AT9191305706T ATE104546T1 (de) 1990-06-22 1991-06-24 Lockvirus impfstoff.

Country Status (10)

Country Link
US (1) US5178882A (de)
EP (1) EP0465081B1 (de)
AT (1) ATE104546T1 (de)
AU (1) AU638841B2 (de)
CA (1) CA2045204C (de)
DE (1) DE69101753T2 (de)
DK (1) DK0465081T3 (de)
ES (1) ES2055539T3 (de)
IE (1) IE65911B1 (de)
PT (1) PT98066B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334394A (en) * 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5462751A (en) * 1990-06-22 1995-10-31 The Regeants Of The University Of California Biological and pharmaceutical agents having a nanomeric biodegradable core
US5464634A (en) * 1990-06-22 1995-11-07 The Regents Of The University Of California Red blood cell surrogate
US5441739A (en) * 1990-06-22 1995-08-15 The Regents Of The University Of California Reduced and controlled surface binding of biologically active molecules
US5460831A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5306508A (en) * 1990-06-22 1994-04-26 The Regents Of The University Of California Red blood cell surrogate
US5460830A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Biochemically active agents for chemical catalysis and cell receptor activation
US6008327A (en) * 1992-03-13 1999-12-28 Akzo Nobel, N.V. Peptides and nucleic acid sequences related to the Epstein Barr virus
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
WO1995012392A1 (en) * 1993-11-01 1995-05-11 The Regents Of The University Of California Biochemically active agents for chemical catalysis and cell receptor activation
DE19511276C2 (de) * 1995-03-27 1999-02-18 Immuno Ag Adjuvans auf der Basis kolloidaler Eisenverbindungen
US6303295B1 (en) * 1995-07-14 2001-10-16 University Of Georgia Research Foundation, Inc. Selenoproteins, coding sequences and methods
PL192016B1 (pl) 1998-11-30 2006-08-31 Cytos Biotechnology Ag Kompozycja, sposób wytwarzania sztucznego, uporządkowanego i powtarzalnego układu antygenu, zastosowanie kompozycji oraz kompozycja szczepionki
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
HUP0202537A3 (en) 1999-08-24 2004-05-28 Teva Pharma A vaccine composition and method of using the same
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU8737501A (en) * 2000-09-14 2002-03-26 Austin Research Inst Composition comprising immunogenic microparticles
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US6887857B2 (en) 2001-04-27 2005-05-03 Scimed Life Systems, Inc. Microparticle protection of therapeutic agents
WO2003051278A2 (en) * 2001-07-10 2003-06-26 North Carolina State University Nanoparticle delivery vehicle
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
JP4726483B2 (ja) 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
KR101228376B1 (ko) 2002-07-18 2013-01-31 사이토스 바이오테크놀로지 아게 합텐-캐리어 컨쥬게이트 및 그의 용도
DE60336902D1 (de) 2002-07-19 2011-06-09 Cytos Biotechnology Ag Impfstoffzusammensetzungen enthaltende amyloid beta 1-6 antigenarrays
WO2010011999A2 (en) * 2008-07-25 2010-01-28 The Regents Of The University Of California Methods and compositions for eliciting an amyloid-selective immune response
US7491554B2 (en) * 2003-04-23 2009-02-17 Tadamasa Fujimura Carrier of a diamond fine particle for immobilizing virus
US7651694B2 (en) * 2004-02-13 2010-01-26 Nod Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of making and using same
US20090041812A1 (en) * 2004-11-01 2009-02-12 Bell Steve J D Therapeutic Calcium Phosphate Particles in Use for Aesthetic of Cosmetic Medicine, and Methods of Manufacture and Use
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
DE102008033175A1 (de) 2008-07-15 2010-01-21 Merck Patent Gmbh Siliciumdioxid-Nanopartikel und deren Verwendung zur Vakzinierung
EP2476753A4 (de) * 2009-09-09 2013-10-09 Tokyo Inst Tech Mit einem eine virusbeschichtung bildenden protein beschichteter artikel und verfahren zu seiner herstellung

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3250596A (en) * 1963-04-08 1966-05-10 Boehringer & Soehne Gmbh Method for determining the virus adsorptive capacity of aluminum oxide
FR1497584A (fr) * 1966-08-11 1967-10-13 Roussel Uclaf Procédé de fabrication de microcapsules
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4329332A (en) * 1978-07-19 1982-05-11 Patrick Couvreur Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them
US4251509A (en) * 1980-01-31 1981-02-17 Wisconsin Alumni Research Foundation Dry particulate vaccine for oral administration
SE441009B (sv) * 1982-03-08 1985-09-02 Kjell Nilsson Sett att immobilisera levande biomaterial i perlformiga polymerer
GB8326633D0 (en) * 1983-08-04 1983-11-09 Unilever Plc Compositions
EP0142193A1 (de) * 1983-10-22 1985-05-22 Akzo N.V. Herstellung von Immunogenen bestehend aus an Glykosid enthaltenden Trägern gebundenen Antigenen und/oder antigenen Determinanten
ZA907737B (en) * 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration

Also Published As

Publication number Publication date
DE69101753T2 (de) 1994-08-25
IE912150A1 (en) 1992-01-01
CA2045204C (en) 1999-01-05
EP0465081B1 (de) 1994-04-20
EP0465081A1 (de) 1992-01-08
AU638841B2 (en) 1993-07-08
CA2045204A1 (en) 1991-12-23
PT98066A (pt) 1992-03-31
AU7921091A (en) 1992-01-02
PT98066B (pt) 1999-03-31
DE69101753D1 (de) 1994-05-26
IE65911B1 (en) 1995-11-29
DK0465081T3 (da) 1994-05-16
US5178882A (en) 1993-01-12
ES2055539T3 (es) 1994-08-16

Similar Documents

Publication Publication Date Title
DE69101753D1 (de) Lockvirus Impfstoff.
LU91324I2 (fr) Vaccin papillomavirus humain Ätypes 6,11,16,18Ü(recombinant, adsorbé)-gardasil/silgard
DE69124800D1 (de) Gentechnologisch veränderte bakteriophagen und sie enthaltende impfstoffe
LU91396I2 (fr) "La combinaison de la protéine L1 recombinante du papillomavirus humain de types 6,11,16 et 18" -Gardasil/Silgard
CY1107571T1 (el) Αυξητικος παραγοντας νευρων ως βοηθητικη ουσια εμβολιου
CA2103887A1 (en) Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
Kodihalli et al. A type-specific avian influenza virus subunit vaccine for turkeys: induction of protective immunity to challenge infection
CA2215203A1 (en) Vaccines for plague
CO4520254A1 (es) Vacunas contra tumores y procedimiento para su produccion
CA2014033A1 (en) Compositions and treatments for pneumonia in animals
CA2066661A1 (en) Viral vaccine conjugates
EP0540645A4 (en) Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells
DE69015305T2 (de) Stabile immunogene Zusammensetzung.
ATE157258T1 (de) Zubereitungen und behandlungen von pneumonia in tieren
SE9202968D0 (sv) New peptides, diagnostic antigens, use thereof, vaccines and medicaments
DK257887D0 (da) Fremgangsmaade til fremstilling af hbcag i gaer og plasmid til brug ved udoevelse af fremgangsmaaden
DE69833568D1 (de) Isolierte stämme von staphylococcus aureus und daraus hergestellte impfstoffe
DE69123252D1 (de) Kreuzreaktive immunisierung gegen influenza
Arnon Artificial Antigens and Synthetic Vaccines a Review
KR920007636A (ko) 신규의 백신체
Movsesyan et al. Neutralization of classical swine fever virus.
Mikhailov et al. The influence of gamma irradiation on hepatitis B virus components and delta antigen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee